The effects of thrombomodulin and activated protein C on the pathogenesis of multiple sclerosis

• Published in: Multiple sclerosis and related disorders 2016-07, Vol.8, p.131-135
• Main Authors: Balkuv, Ece, Varoglu, Asuman Orhan, Isik, Nihal, Isbilen, Banu, Duruyen, Saadettin, Basaran, Recep, Kocer, Abdulkadir
• Format: Article
• Language: English
• Subjects: Activated protein C; Adult; Anti-Inflammatory Agents - therapeutic use; Coagulation cascade factor; Disability Evaluation; Female; Humans; Male; Methylprednisolone - therapeutic use; Middle Aged; Multiple sclerosis; Multiple Sclerosis, Chronic Progressive - blood; Multiple Sclerosis, Chronic Progressive - drug therapy; Multiple Sclerosis, Relapsing-Remitting - blood; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Neuroinflammation; Neurology; Neuroprotection; Protein C - metabolism; Thrombomodulin; Thrombomodulin - blood
• ISSN: 2211-0348; 2211-0356
• DOI: 10.1016/j.msard.2016.05.017

Abstract Background Various molecules of the coagulation cascade are thought to have varying roles in the pathophysiology of multiple sclerosis (MS). We aimed to find new information about the effects of the coagulation cascade molecules to develop new therapeutic strategies for MS. Materials and Methods Patients with MS were chosen from among patients who were followed up at our hospital. We examined the thrombomodulin (TM) and activated protein C (APC) serum levels in patients with MS and the healthy controls. The patient groups were determined as relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) according to the McDonald criteria and between ages of 18 and 70. Results A total of 244 participants, 122 patients with multiple sclerosis and 122 healthy volunteers were included in the study. There was no statistically significant difference in the APC and TM levels between the patients and the healthy controls (p˃0.05), between the patients with RRMS and SPMS (p˃0.05), and between the first day of acute relapse and 10th day of methylprednisolone therapy in the patients with RRMS (p=0.334; p=0.363). We detected a statistically positive correlation only between the expanded disability status scale (EDSS) scores and TM levels in the patient group (p=0.009). Conclusion Treatment with methylprednisolone decreases EDSS score in RRMS relapse. The increase in EDSS is related to level of TM. The changes in level of TM and APC may be indicator for prognosis of MS or treatment modalities to MS.